Duncan Hamish Wright

Excited to share the latest feature in our "Partnering Spotlight" series, where we share some of the connections we are building to foster scientific innovation in healthcare. In this edition, our very own Neha Kaushal sits down with Daniel Anderson, Professor of Chemical Engineering at MIT, to discuss the potential of innovative #mRNA applications in vaccines and novel treatments for genetic diseases. Check out the video to learn more about our collaboration! https://lnkd.in/eHwpyjeY #vaccines #immunoscience

40

1 Comment

🎤 uBriGene Presents Exclusive Sessions at SAPA 2024 @Philly CGT Annual Conference 🎤 🚀 We're thrilled to announce our participation at 2024 @Philly Cell and Gene Therapy Annual Conference with two exclusive sessions aimed at revolutionizing the field: 1️⃣ An Innovative Technology for High Yield and More Stable #CRISPR Guide RNA: Discover how our innovative approach of using in vitro transcription (IVT) in producing guide RNA (#gRNA) that can simplify the process while being more cost-effective and free of organic chemicals. Join us to delve into the future of precision gene editing. 2️⃣ How Could CDMO and Technology Innovations Make CGT Affordable: Dive into the intersection #CDMO of and technological advancements with uBriGene. Learn about our strategies to drive down costs without compromising quality or efficacy. Let's explore how cutting-edge technology can make #CellandGeneTherapy more accessible to all. 2024 @Philly Cell and Gene Therapy Annual Conference brings together the innovators and business leaders to foster collaborations and advance cell and gene therapy in the #GreaterPhiladelphia area. 💡 Join #uBriGene to be at the forefront of innovation and collaboration in the dynamic world of cell and gene therapy and let's make cutting-edge cell and gene technology more accessible!

3

For those interested in Physiologically Based Biopharmaceutics Modeling (PBBM) please check out our recently published article from the 2023 PBBM workshop. It proposes best practices for measuring solubility, dissolution, precipitation and permeability for parameterizing PBBMs, summarizes breakout sessions, and shares PBBM case studies. https://lnkd.in/gda_HH4F

95

2 Comments

Tomorrow at MassBio's Align Summit, I'll be representing CytoReason on a panel with distinguished representatives from Genentech, BigHat Biosciences, BioNTech SE and Locust Walk. In the session "AI Partnerships: Integrating for Strategic Value" we'll bring up best practices for integrating AI/ML into pharma and biotech companies. We'll also discuss the the competitive advantages that these capabilities can unlock, and when to build, buy, or rent these capabilities. Thanks MassBio for organizing this important event, in partnership with Locust Walk and McKinsey & Company. For more info, see the link in comment below.

66

4 Comments

We look forward to hearing Christine Rothe, CDO of iOmx, speak at the 6th Annual Macrophage-Directed Therapies Summit in Boston on October 2nd. Christine will provide key insights into IOMX-0675, our highly differentiated, fully human, cross-specific antibody targeting LILRB1 and LILRB2. In the presentation, Christine will discuss how IOMX-0675 effectively repolarizes the tumor microenvironment, resulting in potent tumor cell killing both 𝘪𝘯 𝘷𝘪𝘵𝘳𝘰 and 𝘪𝘯 𝘷𝘪𝘷𝘰. Also, Christine will highlight IOMX-0675's unique binding profile, which selectively antagonizes the immunosuppressive receptors LILRB1 and LILRB2 while sparing the immuno-activating family members. This differentiation results in superior macrophage repolarization and immune cell activation compared to other antibodies. 🔬   📢 Stay tuned for further updates!   Hanson Wade Group #CancerResearch #Macrophages #immunotherapy #ImmunoOncology

73

My colleague Stephen Pyke recently had the privilege of joining Dr. Tala Fakhouri from the FDA on Episode 2 of ACRO's Good Clinical Podcast. 🎙 They discussed the immense potential of AI in clinical research, delving into topics such as FDA's evidentiary standards for AI and the crucial role of methodological transparency in submissions. Stephen also weighs in on ACRO's AI/ML Principles Statement, an initiative he spearheaded as the Chair of the AI/ML Committee.   Access the episode on Apple Podcasts or Spotify. You can also stream it directly below. Enjoy ─ and let me know what you think in the comments! #ACRO #AIinHealthcare #ArtificialIntelligence

7

Transitions. Did you "cut your teeth" in medicinal chemistry and drug discovery at a Big Pharma, and then transition to a senior leadership position at a biotech or start-up? If so, I invite you to contribute a guest editorial at JMC and describe the experience, pros/cons and other factors that led to your move. #JMEDCHEM

80

2 Comments

Join us at the Drug Discovery Biology Strategy Meeting this November 12th in Boston to hear from Anitha Krishnan, Ph.D, Executive Director of Research at Aviceda Therapeutics. Anitha brings over a decade of innovative scientific expertise in biochemical, immunological, and molecular biology techniques. Her work is pivotal in gene therapy and cell transplantation studies, targeting ocular diseases such as Glaucoma and Age-related Macular Degeneration. She has made significant strides in understanding immune responses in neurodegeneration and autoimmune diseases, particularly through her research on microglial and macrophages and the Fas-FasL system. Anitha will be delving into the "Opportunities and Risks in the Preclinical Development of Molecules that Do Not Cross React with Rodents," offering invaluable insights from her extensive experience in advancing therapeutic approaches from discovery through to clinical trials. Don't miss the opportunity to gain from her comprehensive expertise and her knack for leading innovative preclinical research. #DrugDiscovery #BiomedicalResearch #OcularDiseases #PreclinicalDevelopment #BostonEvents #LifeSciences #StrategyMeetings

53

2 Comments

PTC was excited to learn, share and collaborate with other leading RNA experts at the recent 7th Annual RNA-Targeted Drug Discovery & Development Summit in Boston, MA, and the RNA at the Bench and Bedside IV conference in La Jolla, CA. Anu Bhattacharyya, Kerstin Effenberger, and Marla Weetall from our research team presented on ways PTC is leveraging its leading splicing platform to identify promising therapies for rare diseases with high unmet need. Learn more about our splicing platform here: https://bit.ly/4fi4w6L

135

1 Comment

Exciting updates from Bristol Myers Squibb on #mezigdomide (#CC92480) in combination with tazemetostat and dexamethasone for multiple myeloma! Mezigdomide, a potent CELMoD under investigation, has shown promising preclinical results, being significantly more potent than #iberdomide and other #IMiDs. In the CA057-003 trial (#NCT05372354), 13 patients who had undergone a median of 5 prior lines of therapy received #mezigdomide, #tazemetostat, and #dexamethasone. The overall response rate (ORR) was 53.8%, with higher mezigdomide doses yielding an ORR of 71.4%. The combination demonstrated a manageable safety profile, with grade 3/4 TEAEs occurring in 69.2% of patients. Notably, mezigdomide rapidly degrades Ikaros and Aiolos proteins, inducing apoptosis in multiple myeloma cells and stimulating the immune system. The future of CELMoDs like mezigdomide looks promising as they continue to show high synergy with traditional partners and advanced treatments. Get detailed analysis of the abstract here @ https://lnkd.in/gd-xFFqy Stay tuned for more updates! #MultipleMyeloma #ClinicalTrials #Mezigdomide #BMS #CancerResearch #CELMoDs #healthcare #business #clinicalstudies #clinicaltrials #results #phases #top #abstracts #myeloma #oncology #pharmacautical #hematology

25

We started out Q1 with cautious optimism and the numbers continue to show the confidence was warranted. Biopharma M&A activity more than doubled nationally during the year’s first three months, coinciding with a rebound in venture capital deals as well as a flurry of IPOs. These are all good signs that the drug development cycle is normalizing and should translate into additional funding being available at the seed and Series A stages. Certain to be on the minds of funders and startups attending #AlignSummit24 on Thursday! https://lnkd.in/erEiJm6S  

112

5 Comments

As part of AstraZeneca’s focus on sustainable science, we have set ourselves the ambitious goal to introduce electronic product information (ePI) across all medicines, while ensuring flexibility for patients to access product information through alternative ways if needed. The introduction of ePI brings with it a host of benefits for the planet, patients, and healthcare systems, including: 🌍 Improved accessibility to the most up-to-date information on medicines, available in multiple different languages. 💊 More efficient and wider availability of medicines through digitalisation of labels and quick implementation of label changes. 🍃 Lower environmental impact. If ePI was introduced across all AstraZeneca products, it could potentially save an average of 500,000 trees and 1.6bn litres of water each year. Learn more: https://lnkd.in/gJC-fwtd #WhatScienceCanDo

8

What does it mean to extend the value of model-informed drug development (MIDD) beyond clinical trials and regulatory approval? Certara's Ananth Kadambi and Patrick Smith collaborated with Regeneron's Mohamed Kamal and Samit Ganguly on a recent publication that highlights how integrated modeling approaches can provide considerable value post approval by: ✅ Allowing for earlier strategic preparation for required discussions with payers and HTAs around reimbursement of newly approved assets than generally thought possible ✅ Helping identify data gaps that can be managed by focus data collection during pivotal clinical trials or designing real-word data collection studies ✅ Lowering drug development costs by informing early "no-go" decisions if an asset in early development is found to have limited economic potential Congratulations to our authors. You can read the full article here: https://ow.ly/sOF150SCH1h Read more on this topic: https://ow.ly/LA2J50SCH1f #drugdevelopment #MIDD #clinicaltrials #clinicalpharmacology #marketaccess #reimbursement #realworlddata

32

1 Comment

If you're in Boston on Dec 10-12, come listen to Chuhern Hwang at Wayfinder Biosciences talk about how to use novel RNA binders for drug discovery!

2

A new study from the Center for Integration of Science and Industry at Bentley University shows that differences between the financial structures of large pharmaceutical producers and smaller, emerging biotechnology companies creates synergies that contribute to the pipeline of new, innovative products in response to reductions in drug prices anticipated under the Inflation Reduction Act (IRA). The study in Clinical Trials titled “Modeling impact of Inflation Reduction Act price negotiations on new drug pipeline considering differential contributions of large and small biopharmaceutical companies” suggests that while large pharmaceutical producers would likely reduce R&D spending in response to lower product revenues, R&D in smaller biotechnology companies is not likely to decrease and could sustain both corporate profits and new product approvals at current levels. Therefore, claims that the IRA would reduce the number of new drugs for unmet medical needs are likely false. Authors: Greg Vaughan, Roger Du, CPA, Fred Ledley https://lnkd.in/eARtw54U #InflationReductionAct #innovation #drugprices #drugdevelopment #investment #BentleyUResearch Bentley University Bentley University Center for Health and Business

5

What an interesting read on the shift from traditional patient recruitment methods in rare disease! Learn more about how to optimize patient-driven site engagement in my team member’s blog: https://bit.ly/4eHoBn4

3